{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Super Bad"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Really Bad"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Bad"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"May be Good or May be Bad"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Good"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Really Good"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Super Good"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The palatability and acceptability of lenvatinib oral suspension formulation was assessed using the Palatability Questionnaire. In the questionnaire, participants were asked to answer palatability and acceptability of lenvatinib suspension considering the following elements: taste, appearance, smell, how does it feel in the mouth and overall acceptability in terms of 7 responses: Super good, really good, good, may be good or may be bad, bad, really bad, super bad. In this outcome measure, number of participants have been reported per their overall palatability and acceptability responses.","groups":[{"description":"Participants received lenvatinib 14 mg/m\\^2 suspension, orally, once daily in continuous 21-day cycles until PD, development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor. Participants who were unable to swallow capsules received lenvatinib as an extemporaneous suspension prepared from the capsule.","id":"OG000","title":"All Participants: Lenvatinib 14 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Palatability and acceptability analysis set included all participants who received oral suspension of lenvatinib in Treatment Arm A and who received an optional lenvatinib suspension in Treatment Arm B and who answered at least 1 question in the palatability questionnaire. As planned, combined data for Lenvatinib from Treatment Arm A and B was reported for this outcome measure. Here \"overall number of participants analyzed, N\" signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (Cycle length = 21 days)","title":"Number of Participants Categorized Based on Overall Palatability and Acceptability Questionnaire Responses for Suspension of Lenvatinib","type":"SECONDARY","unitOfMeasure":"Participants"}